CompletedNCT02075528
Early Response to Paliperidone for Schizophrenia
About this title
Read the official source — NCT02075528Medication studyAges 18–65Taiwan
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- TaipeiSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateJuly 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 41
- Sponsor
- Taipei City Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Taiwan
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT02075528
- Official title
Show the full official title
Early Prediction of Clinical Response, Metabolic Change, and Pharmacokinetics in Taiwanese Patients With Schizophrenia Patients Treated by Paliperidone ER: an Open-Label Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Taipei
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Taipei City Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Paliperidone ER.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
